Sacrosidase

Sacrosidase

Names
Trade names	Sucraid
Clinical data
Drug class	Enzyme
Main uses	Congenital sucrase-isomaltase deficiency (CSID)
Side effects	Abdominal pain, nausea, diarrhea, trouble sleeping, headache
Routes of use	By mouth
Typical dose	2 ml with food
External links
AHFS/Drugs.com	Monograph
Legal
Legal status	US: ℞-only

Sacrosidase, sold under the brand name Sucraid, is a medication used to treat congenital sucrase-isomaltase deficiency (CSID). Use may also help support the diagnosis of the condition in question. It is taken by mouth each time a person eats.

Common side effects include abdominal pain, nausea, diarrhea, trouble sleeping, and headache. Other side effects may include allergic reactions. It replace the enzyme sucrase which assists in the breakdown of sugar (sucrose) into simpler forms.

Sacrosidase was approved for medical use in the United States in 1998. In the United States 118 doses costa about 8,700 USD as of 2021. In Europe it is an orphan medicine.

Medical use

Dosage

It is taken at a dose of 17,000 units (2 ml) in those over 15 kg each time they eat.

Chemistry

Sacrosidase is dispensed as a clear solution, with a pale yellow tint, which has a sweet taste. Users must take with food and patients who take Sucraid can maintain a normal diet. Sucraid is packaged in two plastic bottles, each 118ml. A scoop to measure Sucraid is included within the package.

External links

Identifiers:	ATC code: A16AB06 (WHO) CAS Number: 85897-35-4 Y ChemSpider: none UNII: 8A7F670F2Y ChEMBL: ChEMBL1201487 N